News

Foresight Group Announces Strategic Share Buyback Details

Foresight Group Announces Strategic Share Buyback Details

Overview of Foresight Group's Share Buyback Program

Foresight Group Holdings Limited is an esteemed investment manager renowned for specializing in real assets and growth capital. Recently, the company revealed details about its strategic share buyback program, which is part of its ongoing approach to enhancing shareholder value. This initiative was outlined thoroughly in their announcement, where they detailed the transactions conducted on a specific date, including the number of shares repurchased, and additional financial metrics.

Details of Share Purchases

In alignment with its share buyback program, Foresight executed the buyback of 15,000 ordinary shares through Berenberg, a reputable financial institution. The average price paid per share during these transactions was approximately 454.82 pence. This careful management reflects the company’s commitment to its long-term share value strategy.

Share Purchase Breakdown

The share buyback took place over several transactions, which included purchases made at various prices. The most competitively priced shares were acquired at a low of 451 pence, while the highest was at 460 pence. Such precise financial maneuvering indicates robust market engagement by Foresight Group and ensures they are capitalizing effectively during trading.

Treasury Shares and Voting Rights

Post-settlement, the acquired shares will be held in treasury, meaning they will not possess voting rights until released into circulation. With a total of 1,445,164 shares repurchased as part of the ongoing buyback efforts, Foresight currently has 116,347,803 shares outstanding whereby only 113,423,630 of those confer voting rights. This aspect is critical for existing shareholders when considering their participatory rights in corporate governance.

Regulatory Compliance and Reporting

Foresight Group is dedicated to full compliance with market regulations. In compliance with UK regulations, they disclosed detailed trade information about transactions made as part of the buyback. This commitment ensures transparency and accountability as expected by shareholders and market regulators alike.

Why the Buyback Matters

Share buyback programs are an essential feature in enhancing shareholder value. By reducing the number of shares outstanding in the market, Foresight aims to elevate the earnings per share metric, thereby potentially increasing stock prices. For investors, such strategies provide a positive sign regarding the firm's financial health and operational foresight.

The Role of Foresight Group in the Market

Founded in 1984, Foresight Group has built a formidable reputation as a visionary investment manager. They operate across multiple regions, including the UK, Europe, and Australia, focusing on sustainable investment solutions that align with the global transition toward clean energy and responsible development. With years of experience under their belt, their investment approaches are well-balanced between risk and return, enabling access to modern investment opportunities.

Investor Relations Contact Information

For investors seeking further insights or clarification, Foresight Group has designated contacts available:

Foresight Group Investors
Liz Scorer / Ben McGrory
+44 (0) 7966 966956 / +44 (0) 7443 821577
ir@foresightgroup.eu

Berenberg (Joint Corporate Broker)
James Felix / John Welch / Dan Gee-Summons
+44 (0) 203 753 7800

H-Advisors Maitland
Sam Cartwright / Audrey Da Costa
+44 (0) 782 725 4561 / +44 (0) 781 710 5562
Foresight@h-advisors.global

Frequently Asked Questions

What prompted Foresight Group's share buyback program?

The share buyback program aims to enhance shareholder value by reducing the number of shares outstanding, increasing earnings per share.

How many ordinary shares has Foresight purchased?

As part of the buyback program, Foresight has purchased a total of 1,445,164 ordinary shares so far.

What was the lowest price paid for the shares?

The lowest price paid per share during the buyback program was 451 pence.

Will the bought-back shares have voting rights?

The shares acquired through the buyback will not have voting rights as they will be held in treasury.

Who can provide more information on the buyback program?

Investors can contact Liz Scorer or Ben McGrory from the Foresight Group for more detailed inquiries.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Ractigen's Breakthrough in DMD: RNA Activates Utrophin

Updated Category News Views 3

Ractigen's New Fight Against Duchenne: A Personal Take When it comes to biotech advancements, I've seen enough breakthroughs to not get swayed easily. But Ractigen Therapeutics presenting their first-in-human data on RNA activation for Duchenne Muscular Dystrophy (DMD) kind of demands your attention. Folks, they're talking about a potential shift in handling this brutal...

Continue Reading
Venice's Climate Challenge: Rising Seas, Sinking Lands

Updated Category News Views 3

Sea Rise Isn’t Just a Statistics Problem The ordeal of rising seas isn't just about staring at numbers in some spreadsheet, it's a real-world gut punch that's knocking at Venice's door. This city, known for its stunning architecture and winding canals, now serves as the poster child for what happens when Mother Nature and human errors leave a place on the brink of...

Continue Reading
Aetna's 2027 Medicare Plans: Comprehensive Outlook

Updated Category News Views 3

Unpacking Aetna's Medicare Strategy for 2027 Look, if there's one thing you should keep tabs on, it's how Aetna isn't just coasting by in the healthcare arena. These folks are pushing forward with new options for 2027 that prove they're serious about making healthcare not just accessible, but affordable across the board. Aetna, backed by CVS Health (NYSE: CVS), is making...

Continue Reading
Govee Stirs Halloween Chills with New Sarah Gellar Ad

Updated Category News Views 4

Lighting Up Halloween the Hollywood Way When it comes to Halloween, folks go nuts driving up the thrill factor at home, and boy, has Govee nailed it this time around. They've dragged Sarah Michelle Gellar into their spooky mix, transforming homes into eerie masterpieces. And let's face it, who better than the 'Buffy the Vampire Slayer' herself to stir those spine-tingling...

Continue Reading
Honeywell's Supply Line Snags Bait Class Action Risk

Updated Category News Views 8

Stepping into the chaos of the stock market sometimes feels like opening Pandora's box—just when you think you've seen it all, something new tumbles out. This time around, it's Honeywell Aerospace (NasdaqGS: HONA) playing catch with hot coals, and a burning class-action lawsuit smolders in the air. Deadline Looms for Investors in Class Action Heads up, folks! If you've...

Continue Reading
Vatrer Power: Lithium Batteries Revolutionize Golf Carts

Updated Category News Views 2

The humdrum world of golf carts just got a jolt of energy with lithium batteries entering the fray. Vatrer Power, the brain behind some nifty LiFePO4 lithium battery conversions, made some noise at this year's Golf Carting Expo & Dealer Summit in Charleston, South Carolina. Held at the North Charleston Convention Center, this trade show was the industry's premier...

Continue Reading
Kal Plastics Showcases at Design-2-Part Expo

Updated Category News Views 3

Kal Plastics Steps into the Limelight There's a buzz in the air, and it's all about Kal Plastics getting ready to strut their stuff at the Southern California Design-2-Part Show. Now, most folks probably don't spend their nights dreaming about thermoforming and pressure forming, but these guys sure make a case for it. They’ve got their eyes on impressing the crowd with...

Continue Reading
The Real Cost of Cabinet Decisions: Refinish or Replace?

Updated Category News Views 3

Uncovering the Truth Behind Cabinet Decisions When it comes to sprucing up a kitchen, most folks overlook what's hanging on their walls already: those tired old cabinets. Now, are you looking at chucking them out the window for brand-new ones, or can a fresh coat of paint breathe new life into them? Well, that's where Melvin Jones, a painting virtuoso from Lexington,...

Continue Reading
Trading Platforms Poised for Billions by 2031

Updated Category News Views 4

Forecasts and Fierce Digital Landscapes Just when you thought the online trading realm was getting saturated, the numbers are making it clear: there’s still room for growth—even explosive growth. The online trading platform market is eyeing a hike, jumping from a $11.65 billion valuation in 2025 to a projected $18.18 billion by 2031, according to Mordor Intelligence....

Continue Reading

Top 5 Most Recently Viewed Articles

Key Insights from Akero Therapeutics' Recent Financials and Updates

Updated Category News Views 90

Akero Therapeutics Unveils Financial Results and Business Progress In a significant move, Akero Therapeutics, Inc. (NASDAQ: AKRO) disclosed notable advancements in its financial performance and ongoing clinical studies. The company, a pioneer in developing innovative treatments for metabolic diseases, has presented its fourth quarter and total financial results for the...

Continue Reading
SF Intra-city's Exceptional Performance Fuels Dynamic Growth

Updated Category News Views 171

SF Intra-city's Remarkable Growth in 1H 2025 In the competitive landscape of on-demand delivery, SF Intra-city has showcased its resilience and adaptability, reporting impressive results for the period ending June 30, 2025. The Company announced a staggering 48.8% year-on-year increase in revenue, surpassing RMB 10 billion. This remarkable financial performance is...

Continue Reading
Logility Set to Release Q3 Financial Results for FY 2025

Updated Category News Views 190

Logility to Announce Third Quarter Financial Results Logility Supply Chain Solutions, Inc. (NASDAQ: LGTY), a leader in AI-driven supply chain planning software, is preparing to release its financial results for the third quarter of the fiscal year 2025. This important announcement is scheduled to take place after the U.S. financial markets close on an upcoming Thursday....

Continue Reading
Understanding Datadog's Stock and Options Dynamics

Updated Category News Views 217

Exploring Datadog's Stock Performance and Options Insights Recent bullish interest is brewing among financial giants for Datadog, a prominent player in the cloud monitoring space. Our comprehensive analysis of options trading activity for Datadog (DDOG) unveils a series of captivating trends and trading strategies. Started with evaluating the options history for Datadog,...

Continue Reading
Personalis Reports Impressive Revenue Growth for 2024

Updated Category News Views 468

Personalis Releases Preliminary Revenue for 2024 Personalis, Inc. (Nasdaq: PSNL), a frontrunner in advanced genomics focusing on precision oncology, has unveiled its preliminary revenue figures for the fourth quarter and the entirety of 2024. This announcement signals significant growth in the company's offerings and highlights its ongoing commitment to enhancing cancer...

Continue Reading